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Vaccination remains the most effective prophylactic intervention for infectious disease in
the healthcare professional’s toolkit. However, the efficacy and effectiveness of vaccines
decrease with age. This becomes most apparent after an individual reaches 65–70 years
old, and results from complex changes in the immune system that occur during aging. As
such, new vaccine formulations and strategies that can accommodate age-related changes
in immunity are required to protect this expanding population. Here, we summarize the
consequences of immunosenescence on vaccination and how novel vaccination strategies
can be designed to accommodate the aging immune system. We conclude that current
vaccination protocols are not sufficient to protect our aging population and, in some cases,
are an inefficient use of healthcare resources. However, researchers and clinicians are
developing novel vaccination strategies that include modifying who and when we vacci-
nate and capitalize on existing vaccines, in addition to formulating new vaccines specifically
tailored to the elderly in order to remedy this deficiency.
Keywords: immunosenescence, elderly, pneumonia, influenza, human, vaccination, vaccination strategies,
adjuvants
INTRODUCTION
Vaccination represents a cost-effective and efficient way to pro-
tect people from morbidity and mortality due to infections
and, in addition, reduces hospitalizations, and the economic
cost of lost productivity (Whitney et al., 2003; Jefferson et al.,
2005). Since infections often accelerate or exacerbate pre-existing
health concerns in the elderly, prevention of infection by vacci-
nation facilitates healthy, independent living. Current vaccines
and vaccination strategies are effective at protecting healthy
adults and the vulnerable young; however, they are less effective
or even completely ineffective in the elderly. This has become
a growing concern for public health, especially in developed
nations where high birthrates in the mid-twentieth century,
medical advancement, and increasing standards of care have
contributed to a ballooning elderly population (Chen et al.,
2009).
As we age, changes occur in both the innate and adaptive
immune compartments. This phenomenon, termed immunose-
nescence, increases our susceptibility to some, but not all, infec-
tious diseases. While there have been numerous advances in our
understanding of immunosenescence over the past 5 years, there
has yet to be a corresponding increase in availability of novel thera-
pies and vaccines tailored for our aging population. In this review,
we will discuss the growing literature on the aging immune system,
and how this information is being utilized in the design of new
vaccines and vaccination strategies to protect the elderly against a
variety of pathogens.
Please note that this review does not focus entirely on the
mechanisms of immunosenescence. Those who wish to view a
more in-depth review of these mechanisms are encouraged to read
the following: Montecino-Rodriguez et al. (2013) (for overview),
Jenny (2012) (inflammation), Frasca and Blomberg (2011) (B
cells), and Arnold et al. (2011) (T cells).
RECENT FINDINGS IN IMMUNOSENESCENCE
Immunosenescence is defined as age-associated changes in the
immune response. There is a general misconception that the
immune system of the elderly becomes hypo-responsive or broadly
non-functional; however, although many aspects of immunity
decline, this does not occur uniformly and some elements of the
aging immune response are preserved (e.g., CD8+ T cell poly-
functionality) (Lelic et al., 2012) while others are enhanced (e.g.,
pro-inflammatory cytokine production by macrophages) (Olivieri
et al., 2013). Consequently, some researchers suggest that the term
immunosenescence should be replaced with the phrase “senescent
immune remodeling” to better describe the plasticity of the aging
immune system (Dewan et al., 2012). Whatever terminology used,
it is clear that aging of the immune system begins at the level of the
hematopoietic stem cell (HSC), resulting in the increased suscep-
tibility to infectious disease and decreased efficacy of vaccination
in the elderly.
Hematopoiesis is the mechanism of creating blood cells by
the differentiation of HSCs. With age, the proliferative capacity
of these cells, as well as their ability to engraft, decreases and
there is a decrease in lymphoid precursors, which contributes to
skewing toward myeloid precursors (reviewed in Van Zant and
Liang, 2012). The reasons for this are not clear but it appears to
be a combination of epigenetic changes, DNA damage, telomere
shortening, and exposure to chronic age-associated inflammation
(Tollervey and Lunyak, 2012; Tumpel and Rudolph, 2012). The
end result is fewer circulating lymphocytes (of particular impor-
tance is the decrease in naïve T cells) (Sun et al., 2012), increased
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susceptibility to anemia (due to decreased output of erythrocyte
precursors) (Van Zant and Liang, 2012), and increased pyogenic
bacterial infections (due to malfunctioning leukocytes) (Dewan
et al., 2012). An overview of age-related changes in leukocytes is
presented in Figure 1.
AGE-ASSOCIATED CHANGES IN INNATE IMMUNITY/ANTIGEN
PRESENTATION
Recent evidence demonstrates that changes in the myeloid prog-
enitors result in fewer circulating monocytes (Verschoor et al.,
2013), as well as changes in the number of circulating dendritic
cells (DCs) (Verschoor et al., 2013). Age-related changes in tis-
sue resident myeloid cells are not as clear-cut. The numbers
of tissue-associated macrophages are not believed to be dimin-
ished and in some studies were increased, as were splenic CD8−
DCs (Wong et al., 2010), whereas Langerhan’s cells, and plas-
macytoid DCs are decreased (Xu et al., 2012). In addition to
numerical changes in antigen presenting cells (APCs), there are
significant functional changes, which include changes in surface
receptor expression (Pereira et al., 2011), the ability to migrate
to local lymph nodes (Grolleau-Julius et al., 2008; Zhao et al.,
2011), hyper- or hypo-inflammatory responses depending on the
stimuli, and a reduced ability to become fully activated (Paula
et al., 2009; Mahbub et al., 2012). There is conflicting evidence
as to whether antigen presentation and T cell proliferation are
altered with age in vitro (Pereira et al., 2011; Tan et al., 2012); how-
ever, in vivo models demonstrate that antigen presentation and
T cell proliferation are reduced (Pereira et al., 2011; Zhao et al.,
2011), likely due to the reduced migration of DCs to the lymph
nodes and changes in co-stimulatory receptor expression (Li et al.,
2012). Some of the changes in APC function appear to be due to
changes in the aging microenvironment (e.g., the increased levels
of prostaglandin D2 in the aging lung reduce DC activation and
expression of chemokine receptors required for them to migrate to
the lymph nodes; Zhao et al., 2011), whereas other defects appear
to be independent of the microenvironment (Paula et al., 2009).
Recent studies have shown that the inflammatory functions
of various myeloid cell populations are increased with age, caus-
ing chronic inflammation throughout the body (Dewan et al.,
2012). While the reasons for this are up for debate, researchers
have consistently found higher levels of tumor necrosis factor
(TNF) and various pro-inflammatory interleukins (ILs) in the
FIGURE 1 | Age-associated changes in immune cell frequency and
function. A mixture of mouse and human experiments show
differences in both the frequency and function of cells in the innate and
adaptive immune compartments. HSCs in the elderly are skewed
toward differentiation into myeloid progenitors at the expense of
lymphoid progenitors. Elderly individuals have fewer circulating
monocytes and DCs, fewer tissue-associated DCs, normal tissue
macrophages, and increased splenic DCs. Naïve T and B cells
populations are diminished, though mature-like T and B cells are
expanded. As a result, overall antibody production and specificity is
diminished in the elderly. Despite increased numbers of splenic DCs,
antigen presentation is lacking at these sites in the elderly.
Pro-inflammatory cytokine levels are increased in the elderly, as seen in
IL-6 and TNF levels in serum samples.
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serum of elderly individuals when compared to young controls
(Franceschi et al., 2007). There are numerous theories as to why
this occurs, including increased leakiness in the gut leading to
high levels of endotoxin reaching the blood (Meier and Sturm,
2009), chronic viral infections (such as Cytomegalovirus) (McEl-
haney et al., 2012), and increased lifespan of tissue cells such as
macrophages (Harper et al., 2010). This chronic inflammation,
termed “inflamm-aging” has negative consequences on innate
immune responses including reduced cytokine production by
myeloid cells upon stimulation with toll-like receptor (TLR) lig-
ands and reduced antigen presentation (Olivieri et al., 2013).
Overall, innate immunity is abnormal in the elderly, leading to
muted immune responses to pathogens and less efficient transition
to adaptive responses.
AGE-ASSOCIATED CHANGES IN ADAPTIVE IMMUNITY
Vaccine efficacy is most frequently assessed by quantitating the lev-
els of circulating antibodies, or by assessing the opsonophagocytic
capacity of induced IgG. There is some debate about whether the
quality or quantity of antibodies produced with age are decreased
(Blomberg and Frasca, 2011; Sasaki et al., 2011); however, most
studies consistently demonstrate that the elderly produce fewer
antibodies in response to influenza and Streptococcus pneumoniae
vaccination and this reduction correlates with decreased vaccine
efficacy (Cadeddu et al., 2012). In addition, elderly individuals
vaccinated with a “booster” vaccine against influenza produced
less IgG than young controls, thus showing a reduction in sec-
ondary immune responses to the pathogen (Matsushita et al.,
2012). These phenomena may be due in part to defects in APCs
or T cell help, but changes in the distribution and numbers of
B cell subsets also contribute. It is unclear whether total B cell
numbers change with age; however, there is a clear-cut decrease
in the numbers of naïve B cell and their precursor populations
and a corresponding increase in memory-like B cells (Ongradi
and Kovesdi, 2011). This is due in part to output by HSCs
and myeloid skewing and possibly defects in emigration from
the bone marrow. To counterbalance the effects of fewer new
B cells being formed, mature B cells in the periphery tend to
have increased lifespans as well as a greater proclivity to home-
ostatic expansion. As a result, the B cell population becomes
more homogenous and less antigen-specific over time. Studies in
humans have shown a relative decrease in memory B cell pop-
ulations in elderly patients, possibly accounting for decreased
antibody production upon secondary vaccination with influenza
virus. However, some memory responses appear to remain intact,
such as those stimulated by the tetanus vaccine, although these
responses are dependent on pre-booster antibody levels (Hainz
et al., 2005).
Similar to B cells, there are fewer naïve T cells and numbers of
memory T cells increase with age and this is at least partially due
to reduced output of lymphoid precursors from the bone marrow.
Education in the thymus is also impaired since thymic involution,
which begins at birth, is complete by age 50. As a result, the output
of naïve T cells is greatly reduced. Homeostatic proliferation in the
periphery might maintain the numbers of T cells; however, these
cells have a limited T cell receptor (TCR) repertoire, thus reducing
their ability to mount responses to novel antigens.
The end result of thymic involution and longer-lasting periph-
eral T cells is a population shift from predominantly naïve T cells
to T cells with a memory phenotype, especially in the CD8+ T cell
population, which are less capable of clonal expansion upon TCR
stimulation. Recent work has shown that despite a lack of naïve
CD8+ T cell numbers in the elderly, the functionality of CD8+
T cells during acute and chronic viral infections does not corre-
late with age. As such, CD8+ T cell-mediated responses appear to
remain intact even in individuals as old as 85 (Lelic et al., 2012).
While more studies need to be performed on specific T cell sub-
sets and their abilities to mount appropriate memory responses
to a wide range of pathogens needs to be performed, it appears
that vaccines targeting cell-mediated adaptive immune responses
might be more efficacious in the elderly than those eliciting anti-
body responses. It will be interesting to determine whether CD8+
T cells in the elderly are able to mount appropriate responses to
intracellular bacteria, as chronic viral infection often leads to an
exaggerated population of virus-specific memory T cells in older
individuals.
The antigenic diversity of the CD4+ T cell population in the
elderly decreases suddenly and at a greater rate than that of CD8+
T cells, although these cells appear to be more functional than their
CD8+ counterparts. The numbers of CD4+ cells in the periphery
is relatively stable; however, much like CD8+ T cells, there is a
population shift to a memory phenotype. Little is known about
how this shift affects responses to specific vaccine contents. It is
postulated that due to the widespread reduction in the antigen-
reactive T cell repertoire, novel antigens will have less opportunity
to induce a protective memory response. As such, work has begun
on “piggy-backing” vaccines in order to establish immunity to
novel antigens while boosting previous vaccinations.
CURRENT VACCINATION PROGRAMS
Due to the high social and economic costs of infectious disease
in the elderly, most developed countries provide a comprehensive
vaccine program to individuals over the age of 65. These programs
involve both one-time booster and annual vaccinations against
common, vaccine-preventable pathogens such as influenza virus
and S. pneumoniae. Recently, the value of some of these vaccines
has been called into question since, in some cases, they may not
prevent disease in this population (Cadeddu et al., 2012). Conse-
quently, it has been proposed that the best strategy for protecting
the elderly might require developing new vaccines, modifying
existing vaccines, or changing current vaccination practices to
more effectively evoke herd immunity.
INFLUENZA
Severe influenza virus infections are very common in the elderly
and are often accompanied by fatal secondary bacterial infec-
tions. As such, it is generally recommended that everyone over
the age of 65 receive the seasonal trivalent inactivated influenza
vaccine (TIV) as well as pandemic influenza vaccines, if applica-
ble, in order to maintain serum antibody levels. The effectiveness
of this strategy is debatable, with multiple studies of the efficacy
of the vaccine in the elderly being performed with little consen-
sus between studies (Prelog, 2012). This lack of consensus is due
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to a lack of study protocol standardization and outcome para-
meters, as well as insufficient consideration of patient frailty and
study bias. A number of meta-analyses have shown a reduction in
influenza-specific hospitalizations by 27–45% and death by up to
50%, compared to 70–90% efficacy in healthy, young adults (Gross
et al., 1995; Jefferson et al., 2005; Manzoli et al., 2012). Thus, based
on the data that has been collected, it can be concluded that the
efficacy of the influenza vaccine is reduced in individuals over the
age of 65 and is negatively correlated with age within this cohort
(Chen et al., 2009).
It is generally believed that the reduction in influenza vaccine
efficacy in the elderly is linked to multiple defects in the immune
response to the vaccine including reduced anti-hemagglutinin
(HA) antibody titers as well as reduced specificity of these antibod-
ies (Sasaki et al., 2011). The reasons for these diminished responses
are due to a reduced heterogeneity in the B cell pool brought about
by the long-term maintenance of memory B cells and reduced pro-
duction of B cell precursors in the bone marrow, as noted earlier.
Interestingly, the initial inflammatory response to the vaccine also
differs depending on age. For example, elderly individuals pro-
duce elevated serum IL-6 levels, a hallmark of the innate immune
response (Trzonkowski et al., 2009). As such, it appears that both
the innate and adaptive immune responses to the influenza vac-
cine are affected by age, though the specific changes require further
research.
STREPTOCOCCUS PNEUMONIAE
There are currently two forms of pneumococcal vaccine avail-
able. The conjugate pneumococcal vaccines (e.g., Prevnar® 13
and SynFlorix) consist of tetanus, diphtheria, and non-typeable
Haemophilus influenzae carrier proteins conjugated to capsular
polysaccharides of the 13 (Prevnar®) or 10 (SynFlorix) most com-
mon strains found in children (Canada, 2012). Immunization
with these strains induces antibodies that clear nasopharyngeal
carriage and protect from invasive pneumococcal infection and
has dramatically reduced pneumococcal infections in children and
indirectly in the elderly due to a reduction of circulating strains
(see Section Herd Immunity). Since adults, and especially the
elderly, become infected with a broader range of serotypes and
are able to mount anti-polysaccharide antibody responses, the 23-
valent polysaccharide vaccine (Pneumovax® 23 or Pneumo 23®)
are currently recommended (Canada, 2012). Unlike the conjugate
vaccine, immunization with the polysaccharide vaccine does not
induce robust mucosal immunity and, thus, does not result in
reduced colonization or provide herd immunity; however, it has
been shown to reduce mortality due to invasive pneumococcal
disease in healthy young adults (Butler et al., 1993). In the elderly,
however, pneumococcal pneumonia is a far more common man-
ifestation of disease and mortality than is invasive pneumococcal
disease (Jokinen et al., 1993). Although immunization of the
healthy elderly might reduce invasive pneumococcal disease, there
is little or no protection from mortality due to pneumonia in either
the healthy or frail elderly (Dear et al., 2003; Johnstone et al., 2010;
Cadeddu et al., 2012). Better immunization strategies are required
to protect the elderly from pneumonia, which is a leading cause
of mortality and a contributor to decreased quality of life in this
population.
DIPHTHERIA, TETANUS, AND PERTUSSIS
Despite waning levels of diphtheria, tetanus, and pertussis infec-
tion worldwide, these diseases have not been eradicated, with the
elderly having the highest incidence of infection (Chen et al.,
2009). Pertussis, in particular, remains at consistent levels in this
population, though cases are severely underreported (Tan et al.,
2005). The tetanus, diphtheria, and acellular pertussis (Tdap) vac-
cine is recommended for all individuals over the age of 65. A
small number of studies have been performed in order to track
what proportion of elderly individuals have protective antibody
titers, with the results being disconcerting. According to Alagap-
pan et al. (1997), 33% of elderly study participants had protective
levels of anti-pertussis antibodies and that 68% of these patients
were not protected against tetanus. The efficacy of Tdap boost-
ers in elderly patients relies heavily on pre-vaccination antibody
titers, with higher antibody titers before boosting correlating
with positive vaccine responses. Currently, most vaccines that
are suggested for the elderly are not being given at any point
between childhood and the age of 65. It might be that in order
to increase the boosting ability of vaccines later in life, people
should receive boosters intermittently throughout their lifetimes,
before immunosenescence detrimentally affects vaccine responses.
This will ensure that antibody titers (and other measures of vac-
cine efficacy) are at optimal levels and could improve boosting
immunizations later in life. If antibody levels are too low, elderly
individuals are unable to mount appropriate responses and previ-
ous immunizations will not have lasted. This should be taken into
account when public health officials are recommending vaccine
schedules.
NOVEL APPROACHES TO VACCINATION IN THE ELDERLY
The current lack of vaccines approved for use in the elderly,
combined with the limited efficacy of current vaccines in this pop-
ulation, has led researchers to attempt to generate vaccines aimed
at individuals over the age of 65. This is being done by either uti-
lizing available vaccines that are not currently approved for use in
the elderly, or else generating novel vaccine strategies targeting the
aberrant immune responses described earlier in this review. These
strategies can be as simple as increasing vaccine dosage or as com-
plex as introducing viral vector-based vaccines to combat disease.
As mentioned above, the vast majority of this research is being
conducted in order to combat influenza, a fact that is reflected
in the remainder of this review. Figure 2 provides an pictorial
overview of the intervention strategies currently being researched
in the elderly as well as the aspects of the immune response they
are meant to target.
It is important to note that the studies outlined below suf-
fer from the same lack of standardization as the efficacy studies
explained in Section “Recent Findings in Immunosenescence.”
Of particular interest is how researchers define immunogenicity
when testing novel vaccination methods. In the case of influenza,
most studies focus on the generation of systemic antigen-specific
antibodies or opsonophagocytic ability of these antibodies. How-
ever, it has been shown that the activity of T cells (and especially
cytotoxic T cells) might be of equal importance for protection
(McElhaney et al., 2006; Wilkinson et al., 2012). As such, measures
of immunogenicity should include measures of T cell activation.
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FIGURE 2 | Novel vaccine interventions in the elderly. Multiple
novel vaccination strategies are being tested to boost the vaccine
response in the elderly. High-dose vaccines increase antigen
presentation as well ornamentation of follicular DCs with antigen
complexes, increasing B cell activation over time. Various adjuvants
(MF59, AS03, and Matrix-M™) create an “immunocompetent”
environment at the injection site, increasing trafficking of DCs and
monocytes to and from the site, increasing antigen uptake and
presentation to T cells. TLR agonists are used to increase innate
immune cell activation and, therefore, antigen presentation. Finally,
viral vector vaccines increase CD8+T cell responses by promoting
antigen presentation on MHCI.
HIGH-DOSE VACCINES
The best studied, and simplest, approach to increasing vaccine effi-
cacy in the elderly is increasing the dose given. Interestingly, mod-
ification of antigenic dose seems to require a tailored approach to
each age group as in infants low-dose vaccines are more effective
at generating CD8+ T cell responses (Sarzotti et al., 1996). In the
elderly, high-dose vaccines are used to increase antigen delivery
from APCs, such as DCs, to B cells, eliciting a greater antigen-
specific antibody response. Immunization with high-dose vaccines
is believed to increase the numbers of follicular DCs ornamented
with antigen–antibody immune complexes. These cells are capable
of stimulating B cell responses in the absence of new antigen for
long periods of time (El Shikh et al., 2010). A high-dose TIV (60µg
of HA per strain vs. 15µg given normally) has reached phase IIIb
clinical trials with mixed results. One double-blinded, random-
ized, multi-center trial in adults over 65 years of age showed a slight
decrease in influenza incidence in those immunized with the high-
dose vaccine when compared to low-dose controls (DiazGranados
et al., 2013). The increase in protection of 12.6% is misleading,
however, as the 95% confidence interval ranged from −140.5 to
65.8%, showing high variability in the results. A similar phase III
immunogenicity trial showed that protective antibody titers were
significantly higher in individuals given high-dose vaccine and
that these individuals were also more likely to seroconvert 28 days
after vaccination when compared to those receiving a standard-
dose TIV (Falsey et al., 2009). These effects were even seen in
individuals over the age of 75. There were, however, no mea-
surements of vaccine efficacy in regard to influenza incidence or
morbidity, thus limiting the scope of the trial. While increasing the
dose of TIV might increase the immunogenicity of the vaccine, it
remains to be seen whether these increases warrant a change in
vaccine policy for elderly individuals.
While tests have been performed on the efficacy of the high-
dose influenza vaccine, few other vaccines have been tested in
this manner. The conjugate pneumococcal vaccine has recently
been approved for use in individuals over the age of 65. A study
in 2011 showed that increasing the dosage of the vaccine would
increase efficacy without increasing the rate of adverse events
in subjects who were 70 years old or older. In this study, when
patients were given a double dose of PCV7 and PCV9, there
was a dose-dependent increase in local cytokine production and
opsonophagocytic activity of serum antibodies, as well as systemic
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antibody titers when compared to single doses of the two vaccines
(Lode et al., 2011). The study reported that negative reactions
to the two vaccine formulations were comparable. Perhaps more
importantly, the effects of the double dose conjugate vaccine were
significantly greater (for the serotypes used) than the 23-valent
polysaccharide vaccine that is given most regularly to this age
group. While more studies need to be performed to assess the
long-term benefits of the high-dose vs. low-dose conjugate vac-
cine as well as the benefits of these vaccines compared to the
polysaccharide vaccine (and whether these benefits outweigh the
high cost of manufacture for the conjugate vaccines), the work that
has been done shows that increasing the dose of the current vac-
cines on the market might make them better suited to the elderly
population.
ADJUVANTS
With dose increases of vaccines currently in use leading to mixed
results, many researchers have turned to the alteration of vaccine
contents, including the addition of novel adjuvants. A number of
potential TIV adjuvants are being tested in mice, with a few addi-
tional candidates in clinical trial or already in use. The method of
action of these adjuvants is most commonly based on stimulat-
ing enhanced innate immune responses, and especially the influx
and activation of APCs at the site of vaccination (Tetsutani and
Ishii, 2012). This increase in APC activation leads to more robust
adaptive responses and greater immunological memory. In the
elderly, innate immune responses are often enhanced compared to
adaptive responses, making this arm of immunity promising for
exploitation by vaccine adjuvants.
The first adjuvant in use in TIV, MF59, has been included in
influenza vaccines for the elderly in parts of Europe since 1997 and
was recently licensed in Canada for individuals over the age of 65.
MF59 is an oil-in-water emulsion that creates an“immunocompe-
tent environment”at the injection site, leading to increased cellular
infiltration, especially by APCs, in a CCL2/CCR2-dependent man-
ner. This, in turn, amplifies the amount of antigen being presented
to T and B cells (O’Hagan et al., 2012). Due to its widespread
use in elderly populations in Europe, there is considerable data
on the safety and immunogenicity of the MF59-adjuvanted vac-
cine. Elderly individuals vaccinated with this vaccine consistently
respond with high antibody titers and increased rates of sero-
conversion, which result in higher protection. Post-immunization
reactions are more frequent in those receiving the adjuvanted vac-
cine, but are tolerable. Due to variability in the design of efficacy
studies, there is some controversy as to whether the adjuvanted
vaccine provides better protection than regular TIV, although mul-
tiple controlled studies show efficacy greater than 50% (Czajka
et al., 2012; Della Cioppa et al., 2012; Fukase et al., 2012; Mannino
et al., 2012).
A second adjuvant, AS03, is currently in phase IIb clinical trials.
AS03 is very similar to MF59 in that both are predominantly made
up of squalene in an oil-water emulsion. As such, it is believed to
function in a similar manner to that of MF59, although the mech-
anism of action has not been as rigorously determined. A recent
trial in elderly individuals showed a somewhat increased relative
efficacy when compared to non-adjuvanted TIV (McElhaney et al.,
2013). However, this study also suffered from wide variability as
seen in the 95% confidence intervals (12.11%, −3.40 to 25.29),
despite being a very large study (43,802 participants). AS03 also
suffers from allegations of causing narcolepsy in young children
who have received pandemic influenza vaccines containing the
adjuvant (Miller et al., 2013). While these effects have not been seen
in the elderly in safety trials, the negative effects seen in children
could make it difficult to license any vaccine using AS03 as an
adjuvant, especially when it is so closely related to MF59, which
has shown to be safe in numerous trials.
Matrix-M™ (AbISCO® -100, Isconova AB, Sweden) is a
saponin-based vaccine adjuvant that has been tested (in the con-
text of TIV) in mice and has reached Phase I trials in elderly
humans in the past year. Matrix-M™ functions similarly to AS03
and MF59, increasing cellular trafficking to the site of injection and
stimulating T cell immunity (Reimer et al., 2012). Matrix-M™ has
been shown to induce both Th1 and Th2 responses in mice, unlike
the common adjuvant alum, which induces only Th2 responses. A
recent study performed in mice showed Matrix-M™ to be a supe-
rior adjuvant to AS03, alum, and Freund’s Complete Adjuvant
(FCA) (Magnusson et al., 2013). Mice who received Matrix-M™
had more cells traffic to draining lymph nodes and the spleen, as
well as a higher proportion of fully mature macrophages, DCs,
and NK cells at the site of injection. Perhaps most importantly,
there was a significant increase of activated CD4+ and CD8+
T cells in the draining lymph nodes. The researchers then went
on to use Matrix-M™, alum, and AS03 in a vaccine with inacti-
vated influenza virus antigens. Mice received one of unadjuvanted
vaccine or vaccine together with Matrix-M™, AS03, or alum.
After 45 days, spleens were collected and splenocytes were stim-
ulated with the relevant antigens. Splenocytes from mice receiv-
ing Matrix-M™ along with vaccine produced significantly higher
pro-inflammatory cytokine levels, including IL-2 and interferon
(IFN)-γ. IgG responses in these mice were similar to mice receiv-
ing AS03 as an adjuvant. This study shows that saponin-based
adjuvants such as Matrix-M™ might provide increased protection
over other adjuvants that are already in use, or are undergoing
clinical trials now.
Numerous animal studies have been performed regarding TLR
agonists as adjuvants (reviewed in Duthie et al., 2011). It is believed
that it might be possible to increase the activation of the adaptive
immune response by taking advantage of the overactive innate
immune response in elderly individuals. However, it has been
found that the adjuvant activity of TLR agonists can be improved
upon using fusion proteins (Fujita and Taguchi, 2012). One of the
most promising candidates in this regard is the TLR5 agonist fla-
gellin. When flagellin is administered intratracheally to mice, aged
mice respond better than young controls as measured by innate
immune cell trafficking to draining lymph nodes and T and B cell
activation (Bates et al., 2008). However, IgG and IgA production
in the aged mice did not reach the same levels as young controls.
Despite this, the aged mice given flagellin did produce signifi-
cant amounts of these antibodies, possibly highlighting a way to
increase vaccine immunogenicity. Animal studies have also been
performed using flagellin-based fusion proteins with pneumococ-
cal surface proteins and conserved influenza virus proteins, with
excellent results, though these studies were conducted in young
adult mice, not aged (Skountzou et al., 2010; Nguyen et al., 2011).
Recently, a recombinant HA-flagellin fusion protein influenza
virus vaccine (called VAX128) has been tested in healthy adults

























































Dorrington and Bowdish Novel vaccination strategies for the elderly
as well as individuals over the age of 65. VAX128 is designed to
increase immunogenicity to pandemic strains of influenza virus
while limiting the adverse effects that are often associated with
these potent vaccines. Safety tests in humans have shown VAX128
to be well tolerated by the elderly, even at relatively high dosages
(Taylor et al., 2012). More exciting are the immunogenicity data
from these trials. Anti-HA antibody titers, as well as seroconversion
and seroprotection in the elderly participants reached levels com-
parable to young controls and were greater than those found in
individuals vaccinated with TIV. T cell-specific responses were not
measured, however. While much more work will be required in
order to show the efficacy of vaccines based on TLR agonists,
initial results are very encouraging.
VECTOR-BASED VACCINES
Recent work has shown that CD8+ killer T cell responses against
various viruses remain intact in the elderly (Lelic et al., 2012).
However, the bulk of our current vaccines target the humoral
response mediated by CD4+ helper T cells and plasma cells. In
order to exploit aspects of adaptive immunity that remain intact
throughout the aging process, researchers are turning to vector-
based vaccines. Recently, studies have been performed using Mod-
ified Vaccinia virus Ankara (MVA) as a vector for highly conserved
influenza proteins nucleoprotein (NP) and matrix protein 1 (M1).
This vaccine, MVA-NP+M1, improves upon TIV in two ways: it
targets CD8+ T cell responses and does so using antigens that
are common to all strains of influenza, thus eliminating the need
for the serotype matching needed to generate effective TIV vac-
cines each year. Antrobus et al. (2012) performed safety and
immunogenicity studies in volunteers over the age of 50 using
MVA-NP+M1 with mixed results. The vaccine was tolerated well
by all of the participants, with very few adverse events recorded.
Vaccine immunogenicity was measured by measuring the num-
ber of NP- or M1-specific CD8+ T cells producing IFN-γ in the
blood. While individuals between the ages of 50 and 69 responded
very well to the vaccine, those over the age of 70 were unable to
sustain T cell numbers at a protective levels 3 weeks after vacci-
nation. Interestingly, the researchers detected NP- or M1-specific
CD8+ T cells that also produced TNF-α and IL-2 in all of the
age groups, showing that the cells produced were polyfunctional,
an important characteristic of robust immune responses to T cell
antigens (Antrobus et al., 2012). Much like the flagellin recom-
binant vaccine, studies on MVA-NP+M1 are in their very early
stages. However, there is enough evidence to show that these vac-
cines might be effective in the elderly population and so they will
likely enter later-stage clinical trials in the near future.
HERD IMMUNITY
Until the aforementioned challenges in vaccinating the elderly are
overcome, the best protection might be in relying on the herd
effect to protect them indirectly. Herd immunity occurs when the
percentage of individuals vaccinated is high enough that the rate
of disease decreases to the point where the probability of unvacci-
nated individuals contracting disease is minimal (Kim et al., 2011).
In essence, the pathogen is kept at a subclinical level in the pop-
ulation as a whole protecting those who are at risk of infection.
If this approach is to be taken to protect the elderly from infec-
tions in which vaccination is only efficacious in the young, current
vaccination strategies must be altered significantly. For example,
during seasonal influenza infection, most countries target vul-
nerable populations in whom the death rates are highest (i.e., the
elderly, pregnant women, individuals with chronic diseases). Some
also target health care workers who come into contact with these
individuals although vaccination rates among these individuals
often remain too low to be protective (Thomas et al., 2010). Com-
bined these vaccinations strategies may prevent some deaths in
these vulnerable groups, but they are sub-optimal for preventing
infections in the elderly for two reasons. The first is that vaccine
efficacy is lower in the elderly. Even in years in which the influenza
vaccine is well matched and efficacious in young people, efficacy
in the elderly can be<20% (Prevention, 2013). Until these efficacy
rates are improved by novel vaccination strategies, prevention of
infection, rather than vaccination is required. The second reason is
that the attack rate (i.e., the cumulative incidence of infection dur-
ing an epidemic) in the elderly is considerably lower in the elderly
than adults or children (9.3–13.5 per 100 persons≥65 years, com-
pared to 20–40 per 100 persons in children ≤9 years) (Glezen,
1996). It is estimated that as many as 50% of the cases of influenza
in the elderly are caused by exposure to grandchildren (Towers
and Feng, 2012) and that grandparents who are caregivers for
young children have extremely high rates of influenza and pneu-
monia (Cohen et al., 2011a). Consistent with this observation,
both influenza and pneumococcal vaccination of children have
been demonstrated to reduce the incidence of infection, hospi-
talization, and deaths in the elderly (Monto et al., 1969; Whitney
et al., 2003; Hsu et al., 2009; Loeb et al., 2010; Cohen et al., 2011b).
In addition, indirect measures of controlling infections in children
(e.g., school closures) have a pronounced effect of decreasing dis-
ease rates in the general population, including the elderly (Earn
et al., 2012). Although vaccinating children for influenza or pneu-
monia is predicted to be a cost-effective measure (Salo et al., 2006),
when the indirect effects of vaccination are taken into account the
cost-effectiveness of vaccination (as measured by the cost per life-
year saved) increases as much as 15-fold (Ray et al., 2006; Pitman
et al., 2013).
CONCLUSION
Improving the quality of current vaccination programs for the
elderly will require advances in our understanding of how the
immune system ages as well as how we can exploit those changes
to induce more robust, long-lasting responses to vaccine con-
tents. While these advances will take some time to come to
fruition, there are many policy decisions that need to be made
in the meantime in order to better protect our aging popu-
lation. Altering vaccine schedules and targeting at-risk popu-
lations are two ways in which we can improve vaccine effi-
cacy without the need for novel vaccines to come to market.
The vaccination of the elderly is a perfect example of where
researchers (developing new vaccines), clinicians (testing new and
current vaccines), and other healthcare professionals (prescrib-
ing and administering vaccines) need to work together in order
to ensure complete vaccine coverage in this population as well as
data collection and analyses in order to pinpoint areas of need.
Vaccine development would benefit from more standardization
of efficacy trials in regards to both current and novel vaccine
approaches.
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